泽布替尼在B细胞恶性肿瘤治疗中的研究进展  

Research progress on treatment with zanubrutinib for B cell malignancies

作　　者：许新宁 邢晓静[1] Xu Xinning;Xing Xiaojing(Cancer Hospital of China Medical University,Shenyang 110042,China)

机构地区：[1]中国医科大学肿瘤医院,辽宁沈阳110042

出　　处：《实用药物与临床》2023年第8期760-764,共5页Practical Pharmacy and Clinical Remedies

摘　　要：泽布替尼是我国自主研发的一款口服布鲁顿酪氨酸激酶(BTK)选择性小分子抑制剂,通过与BTK结合抑制BTK磷酸化,从而阻断B细胞受体(BCR)信号通路和下游多条信号通路,发挥抗肿瘤作用。在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)、套细胞淋巴瘤(MCL)及华氏巨球蛋白血症(WM)等获批适应证中显示出良好疗效,且耐受性较传统化疗或化学免疫方案更优。在其他类型的B细胞恶性肿瘤中,泽布替尼也逐步走进临床视野。本文结合近年来最新的临床数据,概述泽布替尼在B细胞恶性肿瘤治疗中的研究进展。Zanubrutinib is an oral selective small molecule inhibitor of Bruton tyrosine kinase(BTK)independently developed by our country,which inhibits BTK phosphorylation by binding with BTK,thus blocking B cell receptor(BCR)signaling pathway and multiple downstream signaling pathways,and plays an anti-tumor role.It has shown good efficacy in approved indications such as chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL),mantle cell lymphoma(MCL),and Waldenstr m macroglobulinemia(WM),and is better tolerated than conventional chemotherapy or chemical immunization regimens.In other types of B-cell malignancies,zanubrutinib is also coming into the clinic.This article summarizes the research progress on treatment with zanubrutinib for B cell malignancies based on the latest clinical data in recent years.

关 键 词：B细胞恶性肿瘤 布鲁顿酪氨酸激酶 BTK抑制剂 华氏巨球蛋白血症 泽布替尼 

分 类 号：R730.5[医药卫生—肿瘤]